Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Allen Naomi E, Travis Ruth C, Appleby Paul N, Albanes Demetrius, Barnett Matt J, Black Amanda, Bueno-de-Mesquita H Bas, Deschasaux Mélanie, Galan Pilar, Goodman Gary E, Goodman Phyllis J, Gunter Marc J, Heliövaara Markku, Helzlsouer Kathy J, Henderson Brian E, Hercberg Serge, Knekt Paul, Kolonel Laurence N, Lasheras Christina, Linseisen Jakob, Metter E Jeffrey, Neuhouser Marian L, Olsen Anja, Pala Valeria, Platz Elizabeth A, Rissanen Harri, Reid Mary E, Schenk Jeannette M, Stampfer Meir J, Stattin Pär, Tangen Catherine M, Touvier Mathilde, Trichopoulou Antonia, van den Brandt Piet A, Key Timothy J, Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
Аннотация
METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.
RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).
CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.